Trial
NCT01853228
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Phase1 and Phase 2: decitabine
Why stopped
EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-17